Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Invests In Potential New Drug Class

This article was originally published in The Pink Sheet Daily

Executive Summary

Aptamer therapeutics act like biologics but are chemically synthesized, according to Pfizer collaborator Archemix.

You may also be interested in...



Roche Keeps Shopping: Mirus Acquisition Bolsters RNAi Portfolio

Firm will pay $125 million for access to Wisconsin-based Mirus’ Dynamic PolyConjugates technology.

Roche Keeps Shopping: Mirus Acquisition Bolsters RNAi Portfolio

Firm will pay $125 million for access to Wisconsin-based Mirus’ Dynamic PolyConjugates technology.

Isis Sees A “Fit” With Archemix In Developing Novel Oligonucleotide-Based Drugs

Firms enter strategic alliance that provides Archemix access to four hundred Isis patents for developing proprietary aptamer therapeutics.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel